Dr John Seymour speaks to ecancer at the 2019 ASH meeting in Orlando about the four year analysis of the MURANO trial, which showed a sustained benefit of time-limited venetoclax-rituximab in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL).
He describes the design of the trial and mentions that this time-limited treatment approach provides good disease control and durable time of treatment for most of these patients.
Dr Seymour states that this updated analysis confirm the progression-free survival and overall survival benefit, along with assessing the sensitivity to subsequent therapy after disease-progression.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.